Artal Group’s Avidity Biosciences RNAM Stock Holding History

Artal Group’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-655,555	Closed	-$26.8M	–	78
2024 Q2	$26.8M	Buy	+655,555	New	+$18.8M	0.68%	19
2023 Q4	–	Sell	-300,000	Closed	-$1.91M	–	110
2023 Q3	$1.91M	Hold	300,000	–	–	0.08%	69
2023 Q2	$3.33M	Sell	300,000 -211,962	-41%	-$2.66M	0.1%	75
2023 Q1	$7.86M	Buy	511,962 +11,962	+2%	+$263K	0.47%	47
2022 Q4	$11.1M	Buy	500,000 +250,000	+100%	+$3.73M	0.62%	38
2022 Q3	$4.08M	Hold	250,000	–	–	0.17%	66
2022 Q2	$3.63M	Hold	250,000	–	–	0.19%	72
2022 Q1	$4.62M	Hold	250,000	–	–	0.19%	83
2021 Q4	$5.94M	Buy	250,000 +107,500	+75%	+$2.57M	0.16%	96
2021 Q3	$3.51M	Hold	142,500	–	–	0.08%	123
2021 Q2	$3.52M	Hold	142,500	–	–	0.07%	126
2021 Q1	$3.11M	Hold	142,500	–	–	0.05%	131
2020 Q4	$3.64M	Hold	142,500	–	–	0.08%	115
2020 Q3	$4.01M	Sell	142,500 -32,500	-19%	-$939K	0.1%	104
2020 Q2	$4.95M	Buy	+175,000	New	+$5.05M	0.14%	108

Other funds holding RNAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Artal Group's RNAM Position: Q3 2024 in Review

Artal Group sold out of Avidity Biosciences (RNAM) in Q3 2024, closing a stake of 655,555 shares — an estimated $26.8M sold.

Artal Group first reported a position in RNAM in Q2 2020 and held it in 15 quarters. The position peaked at $26.8M in Q2 2024. 245 funds tracked by Wall St. Rank hold RNAM as of Q3 2024.

Artal Group reported no remaining Avidity Biosciences position as of Q3 2024 after selling out during the quarter.
Artal Group sold 655,555 Avidity Biosciences shares in Q3 2024, an estimated $26.8M.
Artal Group first reported a position in Avidity Biosciences in Q2 2020 and held it in 15 quarters.
Artal Group's Avidity Biosciences position peaked at $26.8M in Q2 2024.
245 funds tracked by Wall St. Rank held Avidity Biosciences as of Q3 2024.

Based on Artal Group's 13F filing for Q3 2024, filed 13 Nov 2024.